Zevra Therapeutics (ZVRA) Net Cash Flow (2014 - 2026)

Zevra Therapeutics' Net Cash Flow history runs 13 years deep, the most recent figure standing at $33.0 million for Q1 2026.

• Quarterly Net Cash Flow rose 739.22% year-over-year to $33.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $57.6 million (up 1122.39% YoY) and the FY2025 annual result came in at $28.6 million, up 394.23% from the prior year.
• Net Cash Flow was $33.0 million for Q1 2026 at Zevra Therapeutics, up from $8.3 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $33.0 million in Q1 2026 and bottomed at -$25.3 million in Q1 2023.
• A 5-year average of -$1.0 million and a median of -$569000.0 in 2023 frame the typical range for Net Cash Flow.
• Annual changes were most pronounced in 2024 — Net Cash Flow plunged 3577.5% — and 2025, when it surged 2633.55%.
• Zevra Therapeutics' Net Cash Flow stood at -$4.8 million in 2022, then surged by 88.27% to -$569000.0 in 2023, then plunged by 3577.5% to -$20.9 million in 2024, then surged by 139.61% to $8.3 million in 2025, then surged by 297.59% to $33.0 million in 2026.
• Business Quant data shows ZVRA's Net Cash Flow at $33.0 million in Q1 2026, $8.3 million in Q4 2025, and $6.7 million in Q3 2025.